Investor Presentaiton
Highlights FY22
a Year of Extraordinary Transactions and Investments for
International Growth and Company Consolidation
.
Sustainability-linked refi stipulated for € 190 M to support M&A
•
Acquisition of Tesi 65% | 35% put & call | EV € 90 M
•
Share Capital Increase ~ € 140 M
Rating Agency Confirms A3.1 Public Rating | A- S&P | A3 Moody's | A-1 Fitch equivalent
RIEDL Entering the Japanese market with pharmacy robots
Gpi Blood New contracts in Greece, Estonia, Saudi Arabia (whole Countries ~ € 14 M)
Global Presence, Local support
Consip Framework Agreement "1" EMR & Telemed:
the consortium led by Gpi equalled ~ € 104 M of direct orders to date
Gpi added up to ~ € 82 M | ~ € 55 M new contracts + ~ € 27 M new direct orders
•
Electronic Medical Record Lombardy Region ~ € 12.5 M
•
.
Pathological Antomy software Veneto Region ~ € 5.9 M
Telemedicine Platform Friuli Venezia Giulia Region ~ € 1 M
7View entire presentation